Trial Search Results
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
The purpose of the study is to determine if the use of activated T cells can effectively treat relapsed disease following allogeneic hematopoietic cell transplantation without causing GVHD.
Stanford is currently not accepting patients for this trial.
Collaborator: National Institutes of Health (NIH)
- Drug: Cytokine Induced Killer Cells
Inclusion Criteria:- Evidence of recurrent or persistent hematologic malignancy following
HLA matched allogeneic hematopoietic cell transplant
- eligible for DLI
- no evidence of GVHD
- stable immunosuppressive regimen
- adequate renal and liver function
Exclusion Criteria:- CML patients who have not received DLI, active infections
Ages Eligible for Study
18 Years - 75 Years
Genders Eligible for Study